

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 May 2026

### Evaluation of protective effects of L-carnitine on the delayed graft function(DGF) in kidney transplant recipients

#### Protocol summary

##### Summary

L-carnitine group, aside with the placebo group, after sign of consent form will be included in this study. Patients will be given oral L-carnitine or placebo at a dose of 3000mg within 8-12 hours before kidney transplantation and 3000 mg daily for 3 days after transplantation. Plasma concentration of NGAL will be assessed at baseline and 2,6,12, 24 and 96 hours after transplantation. Plasma concentrations of total L-carnitine will be evaluated at baseline and 96 hours after kidney transplantation. Major parameters related to kidney function including daily levels of BUN, Serum Cr, urine output, serum electrolytes and demographic information of donor and recipient (eg. Age, sex, weight, BMI, PRA, donor SrCr) will be documented. All patients will be followed for need to dialysis during the first week after transplantation, incidence of acute rejection and transplantation complications in first 2 months after transplantation. Comparison of all mentioned measures between intervention group and placebo group at the end of study will show whether L-carnitine improve graft function or not.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201312233043N9**

Registration date: **2014-02-10, 1392/11/21**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2014-02-10, 1392/11/21

##### Registrant information

###### Name

Simin Dashti-Khavidaki

##### Name of organization / entity

Tehran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 6695 4709

##### Email address

dashtis@sina.tums.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Tehran University of Medical Sciences

##### Expected recruitment start date

2014-01-21, 1392/11/01

##### Expected recruitment end date

2016-01-21, 1394/11/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of protective effects of L-carnitine on the delayed graft function(DGF) in kidney transplant recipients

##### Public title

effects of L-carnitine on kidney graft function

##### Purpose

Prevention

##### Inclusion/Exclusion criteria

Inclusion Criteria: 1. Subjects who are planned to receive kidney transplantation 2. Subjects of 14-70 years old  
Exclusion Criteria: 1. Intercurrent acute and severe infections eg: septic shock, myocarditis, acute pancreatitis 2. History of allergy to carnitine or its analogues 3. History of seizure or at high risk for seizure

4. Intercurrent cardiac/hepatic/pulmonary instability during few days after transplantation

#### Age

From **14 years** old to **70 years** old

#### Gender

Both

#### Phase

2-3

#### Groups that have been masked

*No information*

#### Sample size

Target sample size: **80**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

#### Blinding (investigator's opinion)

Double blinded

#### Blinding description

#### Placebo

Used

#### Assignment

Parallel

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Tehran University of Medical Sciences

##### Street address

Tehran University of Medical Sciences

##### City

Tehran

##### Postal code

#### Approval date

2013-11-23, 1392/09/02

#### Ethics committee reference number

92-03-33-24308

## Health conditions studied

### 1

#### Description of health condition studied

kidney transplantation

#### ICD-10 code

T86.1

#### ICD-10 code description

Kidney transplant failure and rejection

## Primary outcomes

### 1

#### Description

plasma NGAL level

#### Timepoint

baseline and 2,6,12, 24 and 96 hours after transplantation

#### Method of measurement

ELISA

### 2

#### Description

plasma carnitine level

#### Timepoint

baseline and 96 hours after transplantation

#### Method of measurement

ELISA

### 3

#### Description

delayed graft function

#### Timepoint

during first week after transplantation

#### Method of measurement

Scr, urine output, need for dialysis

## Secondary outcomes

### 1

#### Description

Serum sodium concentration

#### Timepoint

at baseline and daily up to day 7 after transplantation

#### Method of measurement

ISE

### 2

#### Description

serum creatinine concentration

#### Timepoint

at baseline and daily up to day 7 after transplantation

#### Method of measurement

Jaffe method

### 3

#### Description

acute rejection during 2 months after transplantation

#### Timepoint

during first and second month

#### Method of measurement

serum creatinine

### 4

#### Description

serum potassium concentration

#### Timepoint

at baseline and daily up to day 7 after transplantation

#### Method of measurement

ISE

## Intervention groups

1

### Description

L-carnitine syrup(500mg/5ml), 3000mg (30ml) day before transplantation and 3000 mg(30ml)(divided in 3 doses) daily for 3 day after transplantation

### Category

Treatment - Drugs

2

### Description

placebo syrup 30ml,day before transplantation and 30 ml (in three divided doses) daily for 3 days after transplantation

### Category

Treatment - Drugs

## Recruitment centers

1

### Recruitment center

#### Name of recruitment center

Transplantation ward, Imam Khomeini Hospital Complex

#### Full name of responsible person

Simin Dashti-Khavidaki

#### Street address

#### City

Tehran

## Sponsors / Funding sources

1

### Sponsor

#### Name of organization / entity

Tehran University of Medical Sciences

#### Full name of responsible person

Dr Younesian

#### Street address

Tehran University of Medical Sciences

#### City

Tehran

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Tehran University of Medical Sciences

### Proportion provided by this source

100

### Public or private sector

empty

### Domestic or foreign origin

empty

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

empty

## Person responsible for general inquiries

### Contact

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Tehran University of Medical Sciences

#### Full name of responsible person

Dr Mohammad-Reza Khatami

#### Position

Associated Professor of nephrology

#### Other areas of specialty/work

#### Street address

Nephrology Research Center

#### City

Tehran

#### Postal code

#### Phone

+216 6581568

#### Fax

#### Email

khatamis@tums.ac.ir

#### Web page address

## Person responsible for updating data

### Contact

#### Name of organization / entity

Tehran University of Medical Sciences

#### Full name of responsible person

Dr Atefeh Jafari

#### Position

Student of Clinical Pharmacy

#### Other areas of specialty/work

#### Street address

#### City

#### Postal code

#### Phone

00

#### Fax

#### Email

#### Web page address

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

empty

### Study Protocol

empty

### Statistical Analysis Plan

empty

### Informed Consent Form

empty

### Clinical Study Report

*empty*  
**Analytic Code**  
*empty*

**Data Dictionary**  
*empty*